N/A N=68 Creating a Patient-centered Report Card for Solid Organ Transplant Candidates
Transplants
Primary: Number of Participants With Correct Response to Question 1 and 2 — 5; 17; 17; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Myelodysplastic Syndromes · Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma
Primary: Phase II: Estimated Percent of Participants Who Experienced Severe Chronic Graft Versus Host Disease (GVHD) — 6.0 Estimated percent of participants
Phase 2 N=19 Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC
MDS · Immunodeficiency · GATA2
Primary: Days to Neutrophil Engraftment — 12 Days
N/A N=60 Health Coaching to Improve Self-Management in Thoracic Transplant Candidates
Self-management · Lung Transplant · Heart Transplant
Primary: Score on Follow-up Self-Management Ability Scale (SMAS-30) — 75.06; 71.47 score on a scale
N/A N=167 Transplant Navigator Intervention to Overcome Barriers to Kidney Transplantation
End Stage Renal Disease
Primary: Number of Steps Completed in Transplant Process — 1.0; 2.8 steps per participant
N/A N=52 Lung Transplant READY Pilot Study
Cystic Fibrosis
Primary: Feasibility of Participants Completing 2-week Study Visit — 25; 25; 0 Participants
N/A N=171 Shear Wave Sonoelastography in Pediatric Liver Fibrosis
Sonoelastography · Elastography · Elastograms
Primary: 2D-SWE Measurements' Capability of Predicting Stages of Fibrosis Based on METAVIR Scoring System — NA; 96.9; 95.2; 1.00 percentage of exams
Phase 2 N=76 Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Acute Graft Versus Host Disease
Primary: Number of Participants With Complete Response (CR) — 34 Participants
Phase 2 N=22 Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E
Fatty Liver
Primary: Biochemical: Number of Patients With Normal Transaminases at End of Treatment. — 6; 6; 6 Participants
N/A N=2,600 Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
Liver Failure, Acute on Chronic
Primary: 28-day Mortality,28-day Liver-transplantation Free Mortality& 28-day Liver Transplantation Rate — 74; 124; 74 Participants
N/A N=48 Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation
Hepatitis C, Chronic · Non-Alcoholic Fatty Liver Disease
Primary: Cholate Shunt Test — 28.0; 37.6; 33.4 SHUNT %
Phase 2 N=46 T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Acute Lymphoblastic Leukemia · Non Hodgkins Lymphoma · Myelodysplastic Syndrome
Primary: Engraftment Rate After Transplant — 100; 100 percentage of participants
Phase 2 N=76 Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
Myelodysplastic Syndrome · Acute Lymphocytic Leukemia · Acute Myelogenous Leukemia
Primary: Percentage of B Cells at One Year Post-transplant in Participants Who Did/Did Not Receive Leuprolide Following Bone Marrow Transplant (BMT) — 22.1; 21.9; 14.3 percentage…
Phase 2 N=20 Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Multiple Myeloma
Primary: Immune Response — 7 Particpants
Phase 2 N=275 Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
Hepatitis C · Hepatitis C, Chronic · Nonimmune Nonviral Causes of Liver Failure
Primary: Number of Participants With Clinical Complications Usually Attributed to Immunosuppression — 12; 4 participants